NIPTGEN PLUS — advanced genomic screening from maternal blood, with clinical support and international coordination.
From a single blood sample to structured reporting — a clear, orderly route.
cfDNA analysis from maternal blood — noninvasive, NGS-based prenatal screening.
View detailsThe right technology, reliable analysis, and clinical interpretation belong to one pathway. Pier Genetic offers a structured, professional route for prenatal screening coordination.
Screening grounded in current genomic technologies.
A model that keeps clinicians at the center.
Dubai-based global network.
Structured management from sampling to reporting.
NIPTGEN PLUS
Advanced prenatal genetic screening based on cfDNA analysis in maternal blood.
One blood sample. Advanced genomic analysis.
Important: NIPTGEN PLUS is a screening test, not a diagnostic test. High-risk results should be reviewed with genetic counseling and invasive options as guided by the clinician.
Cell-free fetal DNA screening from maternal blood — clinical decisions remain with the physician.
Panel content is planned according to gestational age, clinical context, and physician assessment. Below is a summary of NIPTGEN PLUS coverage.
Down syndrome — one of the most commonly screened chromosomal conditions.
Risk assessment for Edwards and Patau syndromes.
Selected sex chromosome aneuploidies (subject to clinical protocol).
Selected microdeletions and copy-number variations in expanded panels.
Fetal fraction assessment included as a quality parameter.
66+ large deletion/duplication options — see product page for details.
NIPT is a screening test. Results must always be interpreted by a healthcare professional with clinical findings.
Results typically support continued routine pregnancy monitoring and scheduled follow-up.
Genetic counseling and invasive diagnostic options are evaluated by the clinician.
Low fetal fraction or technical limits may require a new sample or additional assessment.
Pier Genetic provides an orderly coordination model that supports clinical decision-making.
Appropriate panel and timing determined by the physician.
Dubai-based operational coordination with traceable processes.
cfDNA evaluation with advanced genomic technologies.
Clear reporting format suited to clinical review.
Results interpreted with ultrasound and clinical findings.
Common questions about NIPT and NIPTGEN PLUS.
NIPT (Non-Invasive Prenatal Testing) is a screening method based on analysis of cell-free fetal DNA in maternal blood. It is not a diagnostic test.
Typically from gestational weeks when adequate fetal fraction can be obtained. NIPTGEN PLUS is generally considered from week 10; exact timing is a clinical decision.
No. NIPT is a screening test. High-risk results may lead to invasive diagnostic testing with physician and genetic counseling guidance.
Many NIPT panels can be used in twin pregnancies; suitability depends on pregnancy type and the selected panel.
Results are shared as a structured report through the healthcare professional or clinical channel involved in the pathway.
Pier Genetic is a Dubai-based genetic health company providing clinical support and international coordination for prenatal screening. Analysis is performed through selected partner laboratory infrastructure.
Modern genomic infrastructure
Dedicated support for healthcare professionals
Dubai-based global network
Quality-focused sample and reporting processes
NIPTGEN PLUS, clinical support, and international coordination — reach out to us.
